Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.70 |
| ▸ | CDC25B | P30305 | 5/20 | 0.60 |
| ▸ | CDC25A | P30304 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.57 |
| ▸ | IDO1 | P14902 | 2/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | ATM | Q13315 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30038980 | 1.00 | PTPN1 (0.70) | PTPN1CDC25BCDC25AMEN1KMT2A | |
| SCHEMBL19459046 | 0.89 | PTPN1 (0.80) | PTPN1CDC25BCDC25AMEN1KMT2A | |
| SCHEMBL5810766 | 0.87 | PTPN1 (0.59) | PTPN1CDC25BCDC25AMEN1KMT2A | |
| SCHEMBL5817375 | 0.83 | PTPN1 (0.55) | PTPN1CDC25BCDC25AMEN1KMT2A | |
| SCHEMBL10899337 | 0.83 | PTPN1 (0.55) | PTPN1CDC25BCDC25AMEN1KMT2A | |
| SCHEMBL17969793 | 0.83 | CDC25B (0.60) | PTPN1CDC25BCDC25AMEN1KMT2A | |
| SCHEMBL11828689 | 0.81 | CDC25B (0.89) | PTPN1CDC25BCDC25AMEN1KMT2A | |
| SCHEMBL31619928 | 0.81 | CDC25B (0.89) | PTPN1CDC25BCDC25AMEN1KMT2A | |
| SCHEMBL9628284 | 0.80 | PTPN1 (0.52) | PTPN1CDC25BCDC25AMEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL28549609 | 0.79 | PTPN1 (0.50) | PTPN1CDC25BCDC25AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023149432-A1 | COMPOSITION CONTAINING FLUORINE-CONTAINING MONOMER, METHOD FOR STABILIZING FLUORINE-CONTAINING MONOMER, METHOD FOR MANUFACTURING FLUORINE-CONTAINING POLYMER, AND METHOD FOR MANUFACTURING FLUORINE-CONTAINING MONOMER | ダイキン工業株式会社 | 2023-08-10 | — | — | WO | disclosed |
| US-11541120-B2 | Phosphonium-based ionic drug conjugates | ANTHOS PARTNERS, LP (US) | 2023-01-03 | — | — | US | disclosed |
| US-20200353087-A1 | PHOSPHONIUM-BASED IONIC DRUG CONJUGATES | ANTHOS PARTNERS, LP | 2020-11-12 | — | — | US | disclosed |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | Epizyme, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| CN-108530394-A | A kind of synthesis vitamin K3The method of epoxides | 中国科学院成都有机化学有限公司 | 2018-09-14 | — | — | CN | disclosed |
| US-20170355695-A1 | SMYD Inhibitors | Epizyme, Inc. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355695-A1 | SMYD Inhibitors | Epizyme, Inc. (US) | 2017-12-14 | — | — | US | disclosed |
| EP-2257515-B1 | 1,4-NAPHTHOQUINONE DERIVATIVES AND THERAPEUTIC USE THEREOF | CENTRE NAT RECH SCIENT (FR) | 2017-05-17 | — | — | EP | disclosed |
| US-7253207-B2 | Quinones as disease therapies | CELLGATE, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253207-B2 | Quinones as disease therapies | CELLGATE, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-5155132-A | Nonsteroidal antiinflammatory agents; treating psoriasis | SYNTEX (U.S.A.) INC. (US) | 1992-10-13 | — | — | US | disclosed |
| US-5134161-A | Enzyme inhibitors for skin disorders, antiinflammatory agents | SYNTEX (U.S.A.) INC. (US) | 1992-07-28 | — | — | US | disclosed |
| US-5089657-A | Topical antiinflammatory agents | SYNTEX (U.S.A.) INC. (US) | 1992-02-18 | — | — | US | disclosed |
| US-4786652-A | TOPICAL ADMINISTRATION | SYNTEX (U.S.A.) INC. (US) | 1988-11-22 | — | — | US | disclosed |
| EP-0282006-A1 | Naphtalene anti-psoriatic agents | SYNTEX (U.S.A.) INC. (US) | 1988-09-14 | — | — | EP | disclosed |
| EP-0282056-A2 | Naphthalene anti-psoriatic agents | SYNTEX (U.S.A.) INC. (US) | 1988-09-14 | — | — | EP | disclosed |
| US-4758587-A | Naphthalene anti-psoriatic agents | SYNTEX (U.S.A.) INC. (US) | 1988-07-19 | — | — | US | disclosed |
| US-4251623-A | Imaging process involving thermal decomposition of Te(II) coordination complexes | EASTMAN KODAK COMPANY (US) | 1981-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200353087-A1 | PHOSPHONIUM-BASED IONIC DRUG CONJUGATES | SLC8B1, PHOSPHO1, PBDC1 | PTPN1 3200/4885CDC25B 3503/4885CDC25A 3230/4885 |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | SMYD3, SMYD2, SNRPD3 | PTPN1 2006/4885CDC25B 1373/4885CDC25A 2032/4885 |
| US-20170355695-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | PTPN1 2209/4885CDC25B 1117/4885CDC25A 1756/4885 |
| US-11541120-B2 | Phosphonium-based ionic drug conjugates | SLC8B1, PHOSPHO1, PBDC1 | PTPN1 3200/4885CDC25B 3503/4885CDC25A 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.